Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma. Issue 7 (July 2022)

Record Type:: Journal Article
Title:: Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma. Issue 7 (July 2022)
Main Title:: Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma
Authors:: Vano, Yann-Alexandre
Elaidi, Réza
Phan, Letuan
Fridman, Wolf Herman
Sautès-Fridman, Catherine
Oudard, Stéphane
Abstract:
Is Part Of:: Lancet oncology. Volume 23:Issue 7(2022)
Journal:: Lancet oncology
Issue:: Volume 23:Issue 7(2022)
Issue Display:: Volume 23, Issue 7 (2022)
Year:: 2022
Volume:: 23
Issue:: 7
Issue Sort Value:: 2022-0023-0007-0000
Page Start:: e318
Page End:
Publication Date:: 2022-07
Subjects:: Oncology -- Periodicals
Neoplasms -- Periodicals
Cancérologie -- Périodiques
Oncologie
Oncology
Periodicals
Electronic journals
616.994005
Journal URLs:: http://www.sciencedirect.com/science/journal/14702045 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S1470-2045(22)00331-X ↗
Languages:: English
ISSNs:: 1470-2045
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.090000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 22375.xml